Mineralys Therapeutics announced that lorundrostat, an aldosterone synthase inhibitor, demonstrated a sustained 17.8 mmHg reduction in automated office systolic blood pressure (AOSBP) after 48 weeks in the Transform-HTN trial for uncontrolled or resistant hypertension. Over half of the participants achieved the target AOSBP below 130 mmHg, with the drug well tolerated and no new safety concerns. The U.S. FDA is currently reviewing lorundrostat, with a decision expected by December 22, 2026. This data supports lorundrostat as a promising new treatment option for patients struggling to control hypertension despite multiple medications.
Mineralys Therapeutics' lorundrostat trial data arrives as 88 of 150 health-sector US stocks on Pluang rose today. For readers following health stocks, here is Pluang's market snapshot as of Nov 09, 2026 03:41 WIB: Erasca Inc. (ERAS) gained 8.59% to USD 14.41 with a typical hold time of 4 days, Revolution Medicines Inc. (RVMD) rose 8.24% to USD 192.28 with a 12-day hold, and Hims and Hers Health Inc. (HIMS) increased 8.06% to USD 26.00 with a 24-day hold.
NVIDIA's Board of Directors has started an independent investigation after reports that CEO Jensen Huang was targeted by a foreign intelligence operation. The inquiry, led by independent directors and external counsel, aims to ensure no national secu...
Nvidia's board has launched an independent investigation into CEO Jensen Huang following his admission of infidelity and reports linking him to a foreign intelligence probe. Despite the investigation, the board expressed confidence in Huang and state...
US Senator Richard Blumenthal has given Binance, Tether, and two Trump-associated crypto firms until January 4, 2027, to provide requested financial records amid investigations into alleged illicit transactions and foreign investments. The inquiries ...
Shares of Bitcoin miners Bitdeer and Riot jumped 13% even as Bitcoin fell below $75,000, its lowest since August. The rally is driven by these miners shifting their business model from relying on Bitcoin price to securing long-term AI data center lea...
Nvidia's board is investigating whether CEO Jensen Huang was involved in a foreign intelligence scheme. Despite the probe, Huang will remain in his role without interruption and will cooperate with the investigation. The company emphasized that this ...
